Among older patients with diabetes, metformin was associated with a reduced risk of cancer, but the combination of aspirin and metformin was associated with an increased risk of cancer death.
Cancer patients are more likely to withdraw from clinical trials if the perceived burdens of participation outweigh the perceived benefits.
Computer generated studies compared outcomes with various tumor measurement tactics to determine the impact of variability in results.
Researchers sought to determine prevalence of telemedicine use for initial consultations and its influence on clinical trial enrollment.
Pedmark is the first FDA-approved therapy indicated to reduce the risk of cisplatin-induced hearing loss in children.
Researchers sought to determine which patient demographics and clinical characteristics affected participation in cancer clinical trials.
Experts discuss the challenges and potential resolutions for increasing diversity of clinical trial study populations.
Researchers report on the safety data from the phase 3 ASCENT trial of sacituzumab govitecan in the treatment of metastatic triple-negative breast cancer.
Besremi is a monopegylated, long-acting interferon, which exhibits its cellular effects in the bone marrow in polycythemia vera.
Adding trabectedin to doxorubicin doubled the median progression-free survival.
